Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

Sandhya Manohar, Charat Thongprayoon, Wisit Cheungpasitporn, Svetomir N. Markovic, Sandra M. Herrmann

Research output: Contribution to journalArticle

Abstract

Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients. Methods: A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2019. We included studies that reported outcomes of Ktx recipients who received immune checkpoint inhibitors for cancer treatment. Outcomes of interest were allograft rejection and/or allograft failure. Results: Twenty-seven articles with a total of 44 Ktx patients treated with immune checkpoint inhibitor were identified. Of 44 Ktx patients, 18 were reported to have acute rejection. Median time from immune checkpoint inhibitors to acute rejection diagnosis was 24 (interquartile range, 10–60) days. Reported types of acute allograft rejection were cellular rejection (33%), mixed cellular and antibody-mediated rejection (17%), and unspecified type (50%). Fifteen (83%) had allograft failure and 8 (44%) died. Three patients had a partial remission (17%), 1 patient achieved cancer response (6%), and 5 patients had stable disease (28%). Conclusion: The findings of our study raise awareness of the increased risk for acute allograft rejection/failure following immune checkpoint inhibitors for cancer treatment among Ktx patients, in particular with programmed cell death 1 (PD-1) inhibitors. Future large-scale clinical studies are required to appraise the pathogenesis and plan optimal balanced therapy that helps sustain graft tolerance.

Original languageEnglish (US)
Pages (from-to)149-158
Number of pages10
JournalKidney International Reports
Volume5
Issue number2
DOIs
StatePublished - Feb 2020

Fingerprint

Transplants
Kidney
Safety
Allografts
Transplantation Tolerance
Neoplasms
MEDLINE
Cell Death
Therapeutics
Outcome Assessment (Health Care)
Clinical Trials
Databases
Antibodies

Keywords

  • allograft rejection
  • immune checkpoint inhibitors
  • immunosuppresants
  • kidney transplant
  • PD-1 inhibitor
  • systematic review

ASJC Scopus subject areas

  • Ophthalmology
  • Nephrology

Cite this

Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. / Manohar, Sandhya; Thongprayoon, Charat; Cheungpasitporn, Wisit; Markovic, Svetomir N.; Herrmann, Sandra M.

In: Kidney International Reports, Vol. 5, No. 2, 02.2020, p. 149-158.

Research output: Contribution to journalArticle

@article{56f26597d7b64f63af449fcbf0166692,
title = "Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients",
abstract = "Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients. Methods: A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2019. We included studies that reported outcomes of Ktx recipients who received immune checkpoint inhibitors for cancer treatment. Outcomes of interest were allograft rejection and/or allograft failure. Results: Twenty-seven articles with a total of 44 Ktx patients treated with immune checkpoint inhibitor were identified. Of 44 Ktx patients, 18 were reported to have acute rejection. Median time from immune checkpoint inhibitors to acute rejection diagnosis was 24 (interquartile range, 10–60) days. Reported types of acute allograft rejection were cellular rejection (33{\%}), mixed cellular and antibody-mediated rejection (17{\%}), and unspecified type (50{\%}). Fifteen (83{\%}) had allograft failure and 8 (44{\%}) died. Three patients had a partial remission (17{\%}), 1 patient achieved cancer response (6{\%}), and 5 patients had stable disease (28{\%}). Conclusion: The findings of our study raise awareness of the increased risk for acute allograft rejection/failure following immune checkpoint inhibitors for cancer treatment among Ktx patients, in particular with programmed cell death 1 (PD-1) inhibitors. Future large-scale clinical studies are required to appraise the pathogenesis and plan optimal balanced therapy that helps sustain graft tolerance.",
keywords = "allograft rejection, immune checkpoint inhibitors, immunosuppresants, kidney transplant, PD-1 inhibitor, systematic review",
author = "Sandhya Manohar and Charat Thongprayoon and Wisit Cheungpasitporn and Markovic, {Svetomir N.} and Herrmann, {Sandra M.}",
year = "2020",
month = "2",
doi = "10.1016/j.ekir.2019.11.015",
language = "English (US)",
volume = "5",
pages = "149--158",
journal = "Kidney International Reports",
issn = "2468-0249",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

AU - Manohar, Sandhya

AU - Thongprayoon, Charat

AU - Cheungpasitporn, Wisit

AU - Markovic, Svetomir N.

AU - Herrmann, Sandra M.

PY - 2020/2

Y1 - 2020/2

N2 - Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients. Methods: A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2019. We included studies that reported outcomes of Ktx recipients who received immune checkpoint inhibitors for cancer treatment. Outcomes of interest were allograft rejection and/or allograft failure. Results: Twenty-seven articles with a total of 44 Ktx patients treated with immune checkpoint inhibitor were identified. Of 44 Ktx patients, 18 were reported to have acute rejection. Median time from immune checkpoint inhibitors to acute rejection diagnosis was 24 (interquartile range, 10–60) days. Reported types of acute allograft rejection were cellular rejection (33%), mixed cellular and antibody-mediated rejection (17%), and unspecified type (50%). Fifteen (83%) had allograft failure and 8 (44%) died. Three patients had a partial remission (17%), 1 patient achieved cancer response (6%), and 5 patients had stable disease (28%). Conclusion: The findings of our study raise awareness of the increased risk for acute allograft rejection/failure following immune checkpoint inhibitors for cancer treatment among Ktx patients, in particular with programmed cell death 1 (PD-1) inhibitors. Future large-scale clinical studies are required to appraise the pathogenesis and plan optimal balanced therapy that helps sustain graft tolerance.

AB - Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients. Methods: A literature search was conducted using MEDLINE, EMBASE, and Cochrane Database from inception through April 2019. We included studies that reported outcomes of Ktx recipients who received immune checkpoint inhibitors for cancer treatment. Outcomes of interest were allograft rejection and/or allograft failure. Results: Twenty-seven articles with a total of 44 Ktx patients treated with immune checkpoint inhibitor were identified. Of 44 Ktx patients, 18 were reported to have acute rejection. Median time from immune checkpoint inhibitors to acute rejection diagnosis was 24 (interquartile range, 10–60) days. Reported types of acute allograft rejection were cellular rejection (33%), mixed cellular and antibody-mediated rejection (17%), and unspecified type (50%). Fifteen (83%) had allograft failure and 8 (44%) died. Three patients had a partial remission (17%), 1 patient achieved cancer response (6%), and 5 patients had stable disease (28%). Conclusion: The findings of our study raise awareness of the increased risk for acute allograft rejection/failure following immune checkpoint inhibitors for cancer treatment among Ktx patients, in particular with programmed cell death 1 (PD-1) inhibitors. Future large-scale clinical studies are required to appraise the pathogenesis and plan optimal balanced therapy that helps sustain graft tolerance.

KW - allograft rejection

KW - immune checkpoint inhibitors

KW - immunosuppresants

KW - kidney transplant

KW - PD-1 inhibitor

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85077389696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077389696&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2019.11.015

DO - 10.1016/j.ekir.2019.11.015

M3 - Article

AN - SCOPUS:85077389696

VL - 5

SP - 149

EP - 158

JO - Kidney International Reports

JF - Kidney International Reports

SN - 2468-0249

IS - 2

ER -